Chapter 28: Genetics and DNA-Based Technology in Clinical Biochemistry

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Dive.

If you are listening to this right now, you are probably a college student staring down clinical biochemistry for the very first time.

And

honestly, the sheer volume of information might be feeling a little daunting.

Oh, yeah, it's a lot.

It is a conceptually dense area.

Right.

So take a breath because you are in exactly the right place.

Consider this your personal one -on -one tutoring session.

Today, we are breaking down chapter 28, which is all about the genetics and deoxyribonucleic acid -based technology used in clinical biochemistry.

And the underlying logic here is, well, it's incredibly elegant once you start seeing the Our goal today is to move in a straight line right in the exact order of the chapter.

We'll start with the fundamental biochemical principles of inheritance, move straight into the molecular laboratory to look at the actual diagnostic tools, and then finally connect those lab findings to real -world clinical diagnosis and patient management.

I love that approach.

Yeah.

We really want to show you how a theoretical mutation you see drawn on a whiteboard actually translates to the patient lying in the hospital bed.

Perfect.

So I think the best place to start is with the genetic hierarchy itself.

When we look at the landscape of genetic disorders, clinical biochemistry basically sorts them into three distinct categories.

The widest lens we can use looks at chromosomal disorders.

Right.

That is the macro level.

Chromosomal disorders happen when there is an absence or maybe an abnormal arrangement of entire chromosomes.

And chromosomes are huge.

Exactly.

A single chromosome contains thousands of genes.

So these disorders affect many different gene products all at the same time.

The classic examples you'll see here are Down's syndrome, which is a trisomy for chromosome 21,

Turner's syndrome, which is characterized by a 45 -XO karyotype where a female is missing an X chromosome,

and Klinefelter's syndrome, which is a 47 -XXY karyotype affecting males.

Okay.

So chromosomal issues are massive structural anomalies.

The next year Down would naturally be where just a single gene goes rogue, which brings us to monogenic disorders.

Because the abnormality is isolated to a single gene, it acts as the primary determinant of the disease.

It follows a highly predictable inheritance pattern.

And phenylketonuria is sort of your textbook example of a monogenic condition.

Yeah.

It's classic.

But then you have the third category, which kind of blurs the lines.

These are the multifactorial or polygenic disorders.

Those are a bit more complicated, right?

Very.

They're the result of this intricate dance between multiple interacting genes and environmental or exogenous factors.

Diabetes mellitus fits perfectly here.

You might have a genetic predisposition, but environmental factors often pull the trigger.

To understand how these diseases actually manifest in a person,

we have to clearly separate the blueprint from the building.

That's a great way to put it.

So your genotype is the actual set of genes present in your body.

That's the blueprint.

But your phenotype is the physical expression of that genotype, the building itself.

And that usually materializes through the production of a specific polypeptide or protein.

And, I mean, the scale of that blueprint is just staggering.

Every single nucleated cell in your body contains an identical complement of genes.

But the biological efficiency is what should really catch your attention here.

Only about 1 % of those genes are actually expressed.

Wait, so just 1%, which means the vast majority of our DNA isn't even actively making protein.

Correct.

The genome contains genes of widely varying lengths.

Some stretch over many thousands of bases.

Yet only 10 % of the genome incorporates the actual protein coding sequences, which we call exons.

And the rest.

Well, spliced right into the middle of those functional genes are intron sequences, which have absolutely no coding function.

The rest of the genetic real estate is just taken up by control sequences and intergenic regions.

That's wild.

But even with all that non -coding space, the human body operates on a remarkably streamlined system.

I mean, we rely on just about 20 different kinds of amino acids.

Yeah, just 20.

And the genetic code dictates these amino acids using specific sequences of three DNA bases, known as codons.

From just those 20 amino acid building blocks directed by those three base codons, our bodies can somehow synthesize approximately 100 ,000 varying polypeptides or proteins.

It's an amazing system.

But the clinical biochemistry gets interesting when we look at how that streamlined system breaks down, specifically in those monogenic disorders we mentioned earlier.

Right, the single gene issues.

Exactly.

The malfunction typically happens in one of two ways.

The first is a mutation in a structural gene.

This physically alters the blueprint, which results in the production of an abnormal defective protein.

Everything going wrong in the patient's biochemistry can be traced back to the defective synthesis of that single malformed peptide.

Like having a broken machine on a factory floor.

It's just physically incapable of making the right product.

Precisely.

But the second type of malfunction is an abnormality in a controlling or enhancing gene.

And how is that different?

In that scenario, the structural gene is actually perfect.

The machine on the factory floor is fine, and the protein it produces is structurally normal.

But the controlling gene, think of it as the factory manager, is altering the rate at which the machine operates.

Oh, I see.

Yeah, so you end up with abnormal amounts of a perfectly normal protein.

That protein could be an enzyme, a receptor,

a transport protein, a peptide hormone, an immunoglobulin, or a coagulation factor.

Too much or too little of it throws the entire biochemical balance completely off.

So if these structural and controlling mutations are the culprits behind genetic disease, we need to know how they get passed from parent to child.

Let's walk through the math of inheritance.

Let's do it.

So every inherited characteristic is governed by a pair of genes on homologous chromosomes, one from each parent.

We call these different genes governing the same characteristic alleles.

Right.

And if a person inherits two identical alleles for a trait, they are homozygous.

If they inherit two different alleles, they are heterozygous.

These alleles can reside on the autosomes, the 22 pairs of non -sex chromosomes, or on the sex chromosomes, X and Y.

Autosomal dominant inheritance is usually the easiest to track clinically, simply because it doesn't hide.

Dominant abnormal genes affect anyone who carries them.

Right, anyone.

That includes heterozygotes who have one normal and one abnormal allele, and homozygotes who carry two abnormal alleles.

Though the homozygotes usually suffer much more severe clinical symptoms.

The statistical breakdown here is critical for understanding family risk.

Imagine one parent is heterozygous for an abnormal dominant gene, meaning they carry one abnormal and one normal allele, and the other parent is entirely normal.

There's a 50 % chance any offspring will inherit that abnormal gene and express the disease.

Okay, 50%.

But if both parents happen to be heterozygous, the odds jump.

Statistically, three in four children will be affected.

A quarter will be homozygous for the abnormal gene, and half will be heterozygous.

You can usually spot this pattern in a clinical pedigree, because every affected individual has at least one affected parent.

It simply does not skip generations.

And clinically, normal offspring do not carry the gene secretly.

Familial hypercholesterolemia perfectly demonstrates this dominant pattern.

But autosomal recessive inheritance, on the other hand, is the sneaky one.

Sneaky how?

It hides.

Recessive abnormal genes only express the disease in homozygous offspring, those who inherit the abnormal allele from both parents.

Heterozygous individuals carry one mutant allele, but appear completely clinically normal.

They are hidden carriers.

Ah, which completely changes the risk profile.

If two carrier parents have children, they look entirely healthy.

But statistically, they face a one in four chance of having a child with the disease.

Because the trait can be masked in carriers, the clinical consequences often appear to skip generations entirely.

Recessive disorders generally show up less frequently in affected families, compared to dominant ones.

But they tend to be far more clinically severe when they do manifest.

Cystic fibrosis is your primary clinical correlation here.

The inheritance rules shift yet again when we look at the sex chromosomes, specifically X -linked recessive inheritance.

Females have two X chromosomes, while males have one X and one Y.

So they don't have a backup.

Right.

Because females have a backup, an abnormal X chromosome is usually latent when paired with a normal X.

But in males, whatever is on that single X chromosome is active and expressed, because the Y chromosome doesn't provide a matching allele to mask it.

So if a mother is a carrier with one abnormal X chromosome, she appears perfectly healthy.

But statistically, half of her sons will inherit that abnormal X and manifest the disease.

And half of her daughters will inherit the abnormal X and become hidden carriers just like her.

But flip the scenario.

If the father has the disease and the mother is normal, none of their sons will be affected.

Because sons only inherit the father's normal Y chromosome.

Exactly.

However, every single one of his daughters will be a carrier, because they must inherit his single abnormal X chromosome.

Inherited disease manifesting almost exclusively in male offspring while being silently carried by females is the definitive hallmark of X -linked inheritance.

Hemophilia is the classic example here.

And females only show the disease in the incredibly rare event that an affected father and a carrier mother both pass on the mutant gene.

Right.

Now, there are a few rare nuances to keep in mind, like X -linked dominant inheritance, where both carrier women and affected men show the disease such as in familial hypophosphatania.

We also see multiple alleles governing a single characteristic, producing complex disease patterns like the hemoglobinopathies.

And sometimes you see incomplete penetrance where a dominant gene simply fails to manifest physically, making it look like a dominant trait magically skip degeneration.

Okay, before we transition from theoretical inheritance to the physical lab tools used to find these genes, there is a vital concept the chapter brings up called epigenetics.

Yes, very important.

Epigenetics involves the inheritance of a characteristic without any change to the actual DNA sequence.

Instead, the gene expression is altered by chemical modifications,

like histone acetylation or DNA methylation.

So the genetic code remains identical.

Completely identical.

But the physical access to read that code is turned on or off.

We will definitely circle back to that later because it's a massive frontier.

But for now, let's look at how we actually analyze the sequence itself in the lab.

Picture DNA as a massive double helix.

It is a nucleoside polymer built from hundreds of millions of bases, adenine, cytosine, guanine, and thymine, where A always pairs with T and C always pairs with G.

And the physical structure of that helix dictates how we manipulate it.

The two strands are anti -parallel, meaning they run in opposite directions.

They have a distinct polarity, reading from a 5' end down to a 3' end.

Got it.

When a cell replicates, an enzyme called DNA polymerase slides along the template strand from 3' to 5',

assembling the new complementary chain in the 5' to 3' direction.

So to look at a patient's DNA, we first have to extract it from a blood sample, which is a three -step purification process.

Right.

Let's break that down.

First, we use leukocyte lysis to aggressively break open the white blood cells.

Second, we run a chloroform or phenol extraction.

This acts as a chemical solvent to strip away and remove any contaminating proteins.

Finally, we treat the sample with protein A's and RNA's enzymes to chew up and destroy any leftover protein or RNA debris, leaving us with pure genomic DNA.

Once we have that pure DNA, we usually need to separate it by size.

DNA naturally carries a strong negative charge at a neutral pH.

We exploit this by using a technique called electrophoresis.

We apply an electrical current to pull the negatively charged DNA through a gel -like molecular sieve toward a positive pull.

And smaller pieces move through the sieve faster than larger pieces.

Exactly.

And the type of sieve we use depends on what we are looking for.

If we want to separate larger chunks of DNA, anywhere from 100 ,000 to 10 ,000 base pairs, we use agarose gels.

But if we need a much tighter, finer molecular sieve to separate tiny DNA fragments, we switch to polyacrylamide gels.

The challenge is that once the DNA is separated on the gel, it is completely invisible.

To actually locate the specific genetic sequence we care about, we rely on probes and a process called hybridization.

A DNA probe is a custom -built sequence of DNA that perfectly matches the mutation we are hunting for.

And we insert this probe into a plasmid, which is a small circular piece of double -stranded DNA.

Right.

And this next part is brilliant.

We artificially force bacteria to take up this plasmid through a process called transformation.

We use divelinecations, basically positively charged ions, to temporarily poke microscopic holes in the bacteria's cellular armor, allowing the plasmid to slip inside.

To ensure we only grow bacteria that successfully absorbed our probe, we include a selectable marker in the plasmid, usually a gene for antibiotic resistance.

Then we grow the bacteria in a broth containing that specific antibiotic.

Any bacteria that fail to take up the plasmid are killed.

The ones that survive multiply rapidly, creating millions of perfect copies of our DNA probe.

We then extract those probes and label them so we can actually see them.

Historically, labs used radioactive phosphorus -32.

But today, we often use non -radio -labeled methods like horseradish, peroxides -enhanced chemiluminescence.

It basically acts as a highly sensitive glow -in -the -dark tag.

Exactly.

To make the labeled probes stick to the patient's DNA on the gel, we first heat the patient's DNA.

This thermal energy breaks the hydrogen bonds, melting or denaturing the double helix into two single strands.

We then introduce the probe and slowly lower the temperature, allowing the strands to anneal or rejoin.

We control this binding through a concept called stringency.

Stringency?

Yeah.

By carefully adjusting the temperature and the ionic strength of the solution, we create a Goldilocks environment.

If the stringency is high, the probe will refuse to belong to anything except a 100 % perfect match in the patient's genomic DNA.

But genomic DNA is far too massive to run through a gel intact.

We have to cut it into manageable, specific pieces first.

We do this using restriction endonucleases, which basically act like molecular scissors.

Right.

These are specialized enzymes originally derived from bacteria, like Ikari, which comes from Ischerechiachole.

And these molecular scissors don't just cut randomly.

They act like a scanner looking for a very specific barcode, which we call a restriction site.

Furthermore, these sites are often palindromic.

Which means they read the same forwards and backwards.

Yeah.

Ikari, for example, specifically hunts for the sequence GATTC on the 5' to 3' strand.

If you read the opposite anti -parallel strand, it mirrors that exactly, CTTK.

It only cuts when it sees that exact barcode.

The diagnostic power of this relies on normal human variation, known as polymorphism.

The base pairs in our DNA naturally differ slightly from person to person.

If a polymorphic change occurs in a non -coding intron region, it doesn't affect the final protein, so the patient is totally healthy.

However, if that tiny sequence change happens to alter the barcode at a restriction site, the molecular scissors will no longer recognize it and won't cut the DNA there.

Alternatively, a completely new mutation might accidentally create a brand new restriction site where none existed before.

So because of these individual genetic differences, when we take DNA from different people and cut it with the exact same enzyme, we end up with uniquely sized fragments.

Exactly.

We call these restriction fragment length polymorphisms, or RFLPs.

RFLPs.

And when you combine the concept of RFLPs with variable number tandem Peet's VNTRs, which are short, repetitive sequences scattered naturally throughout the human genome, you get the entire foundation for DNA fingerprinting.

To visualize these specific cut fragments, we use blotting techniques.

In southern blotting, which is used for DNA, we use alkaline conditions to denature the DNA fragments directly on the gel.

We then transfer them to a durable nitrocellulose or nylon membrane using capillary action.

Then we bake the membrane or hit it with UV light to permanently fix the DNA in place and wash it with our labeled probe.

If a clinician needs to analyze RNA instead of DNA, the exact same process is used, but it's called northern blotting.

And that's highly relevant clinically, right?

Oh, absolutely.

For instance, in thalassemia, the mRNA produced from the globin gene is abnormal in either its amount or its physical size.

A northern blot will reveal that discrepancy immediately.

We also utilize microarrays or DNA chips.

These allow us to rapidly detect changes in gene expression across different cells by binding microscopic amounts of known DNA sequences onto a solid surface.

But all of these techniques assume you have an adequate biological sample.

What happens if you only have a microscopic trace of DNA?

This is where polymerase chain reaction, or PCR, revolutionize the field.

PCR allows us to exponentially amplify a tiny DNA segment up to a million fold.

The biological engine of PCR is an enzyme called TAC polymerase.

And the origin of TAC polymerase is incredible.

It is a heat -stable DNA polymerase harvested from Thermus aquaticus, an organism that evolved to survive in boiling hot springs.

Yeah, because it evolved in extreme heat, it doesn't get destroyed by the high temperatures needed to manipulate DNA in the lab.

The PCR process happens in an automated thermal cycler.

The reaction mixture contains the patient's template DNA, a massive supply of the four free nucleotides, specific oligonucleotide primers designed to flank the target sequence, and the TAC polymerase.

The machine then cycles through three specific temperatures.

First, it hits 95 degrees Celsius to melt and separate the DNA strands.

Then it rapidly cools down to 50 degrees Celsius.

This cooler environment allows the specific primers to physically bind or anneal to the target segment you want to copy.

Finally, the temperature rises to 72 degrees Celsius.

This is the optimal working temperature for TAC polymerase.

It latches onto the primer and rapidly extends the new DNA strand, incorporating 50 to 100 nucleotides every second.

Then the machine spikes the heat back up to 95 degrees to separate the newly formed strands and the cycle repeats.

DNA duration, primer annealing, and primer directed extension.

And there is a beautiful moment of precision in this process.

During the first two thermal cycles, the newly synthesized DNA strands are of an indeterminate, messy length.

But exactly in the third cycle, the final products of the precise targeted length are achieved for the first time.

From that third cycle onward, the precise target sequence multiplies exponentially.

We can even tweak PCR to hunt for tiny single -letter mutations using the Amplification Refractory Mutation System, or ARM.

DNA simply cannot undergo PCR amplification if the primer has a mismatch right at its 3' end.

ARMS leverages this by using specific primers that will only allow amplification to proceed if a specific single nucleotide mutation is present.

It's an elegant binary test for point mutations.

So we've walked through the genetics, the extraction, the cutting, and the amplification.

How does a clinical biochemist actually use this data to inform patient management?

Let's look at how a pedigree is mapped using a southern blot.

Imagine a family with a known X -linked genetic condition.

We take a sample from a clinically affected male and run a southern blot.

The probe highlights a very specific 2 .8 kilobase band of DNA.

Because we are mapping the family inheritance, we test his mother, and we see that exact same 2 .8 kilobase band confirming she passed it to him.

We then test his sisters.

The blot reveals the 2 .8 kilobase band in only one of the sisters.

This definitively identifies her as a hidden carrier, providing vital exact information for genetic counseling regarding her future pregnancies.

The shift from old laboratory methods to DNA -based technology has completely upgraded how we diagnose specific diseases.

Take cystic fibrosis.

The disease is frequently caused by a specific 3 -base pair deletion in codon 508 of the cystic fibrosis chloride channel gene.

Because we know exactly what we are looking for, we use PCR to detect this specific defect.

This allows clinicians to easily screen for healthy carriers or test affected pregnancies early using chorionic villus sampling.

Muscular dystrophies are another major application.

PCR techniques are heavily utilized to detect carriers and patients affected by both Duchenne's and Becker's muscular dystrophies.

Based strictly on the text, both of these severe diseases are tracked back to deletions in the dystrophin gene located on chromosome 21.

Chromosome 21?

Yes.

Duchenne's results from a massive deletion causing a complete absence of the dystrophin protein, whereas Becker's results from a mutation yielding a partially functioning albeit defective dystrophin protein.

The diagnostic upgrade is incredibly apparent when managing lipid disorders too.

Familial hypercholesterolemia, that autosomal dominant condition we discussed earlier, is typically a defect of the LDL receptor on chromosome 19.

Right.

And a related variant is familial defective APOB100, which is caused by a precise mutation at the 3500 position.

PCR screening identifies these defects rapidly and definitively.

And we see PCR entirely superseding older protein -based lab methods.

Consider apolipoprotein E, which shows natural polymorphism.

The specific APOE4 allele is strongly associated with the development of Alzheimer's disease.

Historically, labs used a protein technique called isoelectric focusing for APOE phenotyping.

The problem was that post -translational modifications, chemical changes to the protein while it was circulating in the blood, frequently caused confusing discordant laboratory results.

Which is bad.

Very bad.

By switching to PCR methods to directly characterize the underlying APO genotype, we bypassed the protein entirely, eliminating those errors.

We saw the exact same diagnostic evolution with alpha -1 antitrypsin deficiency, a condition that can lead to severe emphysema or liver cirrhosis.

Because there are over 50 genetic variants of the enzyme, the old protein isoelectric focusing methods were cumbersome.

Today, direct PCR detection of the clinically significant alleles has completely taken over patient screening.

Hamochromatosis and iron overload disorder is now routinely diagnosed not just by looking at iron levels, but by using DNA techniques to identify the specific C282Y or H60 3D mutations within the HFE gene.

Sickle cell anemia is diagnosed by pinpointing a single A to T nucleotide substitution in the sixth codon of the beta -globin gene.

And that can be detected even before birth during amniocentesis using allele -specific hybridization.

And the applications extend far beyond our own human genome.

The precise targeting of PCR is used to verify the presence of infectious agents by amplifying pathogen -specific DNA sequences hidden in a patient's blood.

It is the standard for diagnosing and managing HIV, Hepatitis C, and even gastric infections like Helicobacter pylori.

Furthermore, analyzing highly variable regions like VNTRs remains the absolute gold standard for determining paternity and identifying biological tissues in forensic science.

The clinical integration of this technology is profound, but as we wrap up, I want to leave you with a broader thought.

Oh, absolutely.

Throughout this session, our focus has been heavily anchored on the 10 % of the genome that actively codes for proteins and the diseases caused by mutations within those structural and controlling sequences.

But recall our early mention of epigenetics.

How environmental factors trigger DNA methylation or histone modifications to alter gene expression without ever changing the sequence itself.

Right.

Could unlocking the vast, unmapped, non -coding regions of our DNA and understanding these epigenetic switches be the key to finally conquering complex, multifactorial diseases like diabetes that blur the line between a patient's genetics and their environment?

That is an excellent question to keep in the back of your mind as you continue studying.

We've covered the entire journey today, moving from the mathematical rules of inheritance straight through the extraction, cutting and amplification of the lab, all the way to diagnosing the patient at the bedside.

From everyone here at the Last Minute Lecture Team, thank you for joining us for this tutoring session.

Good luck with clinical biochemistry.